Home
Tools
Resources
Blog
About

Search

Medicines Law & Policy Research and resources on intellectual property and health

Home
Tools
Resources
Blog
About

Tag: market exclusivity

European Pharmaceutical Legislation Needs Exceptions to Data and Market Exclusivity to...

Ellen 't Hoen - May 21, 2018

Recent Posts

Opmerkingen bij de notitie Dwanglicenties van B.J. Bruins, Minister voor Medische Zorg.
How patents, data exclusivity and SPCs interact to extend market exclusivity of medicines: the example of Truvada
European Pharmaceutical Legislation Needs Exceptions to Data and Market Exclusivity to Protect European Patients from High Drug Prices
Will the European Court of Justice put a stop to the evergreening of Truvada patents?

Posts by Subject

Access to Medicines Cancer competition law Compulsory licensing compulsory licensing for export CRISPR Data exclusivity Delinkage dolutegravir European Commission European Union France Gilead Hepatitis C HIV India innovation Italy LDCs market exclusivity Medicines Patent Pool Medicines Pricing Netherlands Orphan Drugs Patents PrEP R&D Scotland Sofosbuvir Spain Supplementary Protection Certificates TRIPS flexibilities Truvada United Kingdom United Nations High Level Panel WHO WIPO WTO

Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: info@medicineslawandpolicy.net.

This work is licensed under Creative Commons.